HCM:NGS-Hutchison China MediTech Limited (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | Nasdaq Global Select

Last Closing

USD 18.16

Change

-0.83 (-4.37)%

Market Cap

USD 1.51B

Volume

0.19M

Analyst Target

USD 35.28
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Hutchison China Meditech Ltd is a biopharmaceutical company. The Company along with its subsidiaries is engaged in researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

+0.64 (+0.46%)

USD 13.68B
VTRS Viatris Inc

-0.59 (-5.00%)

USD 13.36B
ITCI Intracellular Th

-1.44 (-2.15%)

USD 7.72B
LNTH Lantheus Holdings Inc

+1.39 (+1.87%)

USD 4.49B
ALKS Alkermes Plc

+0.16 (+0.66%)

USD 4.11B
ALVO Alvotech

+0.06 (+0.44%)

USD 3.79B
AVDL Avadel Pharmaceuticals PLC

-0.42 (-2.58%)

USD 2.99B
INDV Indivior PLC Ordinary Shares

+0.09 (+0.51%)

USD 2.93B
EVO Evotec SE ADR

+0.08 (+1.54%)

USD 2.51B
AMPH Amphastar P

+0.22 (+0.52%)

USD 2.06B

ETFs Containing HCM

AXJV 0.00 % 0.35 %

N/A

N/A
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

-0.22 (0%)

USD 0.02B
CHNA 0.00 % 0.62 %

N/A

N/A
CHNA 0.00 % 0.79 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.28% 59% D- 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.28% 59% D- 54% F
Trailing 12 Months  
Capital Gain 19.16% 73% C 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.16% 73% C 74% C
Trailing 5 Years  
Capital Gain -39.59% 60% D- 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.59% 60% D- 30% F
Average Annual (5 Year Horizon)  
Capital Gain 2.69% 62% D 54% F
Dividend Return 2.69% 62% D 50% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.02% 56% F 38% F
Risk Adjusted Return 5.98% 67% D+ 46% F
Market Capitalization 1.51B 91% A- 84% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 27.32 49% 34%
Price/Book Ratio 4.04 26% 27%
Price / Cash Flow Ratio 12.76 12% 21%
Price/Free Cash Flow Ratio 32.84 8% 7%
Management Effectiveness  
Return on Equity 14.65% 88% 84%
Return on Invested Capital 1.78% 68% 63%
Return on Assets 1.00% 73% 68%
Debt to Equity Ratio 6.60% 63% 75%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.